Chemomab Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemomab Therapeutics (CMMB).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$27Upside to Avg. PT+2034.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2025	Oppenheimer	Jeff Jones	PT Raise	Outperform	$10→$25
May 16, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$11→$10
Feb 20, 2025	Maxim Group	Michael Okunewitch	PT Raise	Buy	$4→$7
Nov 15, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$13→$11
May 13, 2024	Maxim Group	Michael Okunewitch	Initiate	Buy	$4
May 6, 2024	Oppenheimer	Jeff Jones	Upgrade	Perform→Outperform	$6
Mar 8, 2024	Oppenheimer	Jeff Jones	Maintained	Perform	—
Dec 19, 2023	Roth MKM	Dylan Dupuis	Reinstates	Buy	$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and raises the price target from $10 to $25.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and raises the price target from $4 to $7.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

Oppenheimer analyst Jeff Jones reiterates Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Outperform and announces $6 price target.

Benzinga Newsdesk

Chemomab Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Chemomab Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

People Also Watch

People Also Watch

Chemomab Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Chemomab Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PROOppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PROMaxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PROOppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PROMaxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PROOppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

People Also Watch

People Also Watch

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target